When the Third Time Is Not the Charm—Trial Outcomes in Idiopathic Pulmonary Fibrosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

When the Third Time Is Not the Charm—Trial Outcomes in Idiopathic Pulmonary Fibrosis

Published:2024-08-06 Issue:5 Volume:332 Page:374
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Zamora Ana C.¹²,Ortega Victor E.³⁴,Carmona Eva M.⁵⁶

Affiliation:

1. Department of Internal Medicine, Division of Respiratory Medicine, Mayo Clinic, Phoenix, Arizona

2. Interstitial Lung Disease Clinic, Mayo Clinic, Phoenix, Arizona

3. Center for Individualized Medicine, Mayo Clinic, Phoenix, Arizona

4. Associate Editor, JAMA

5. Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota

6. Interstitial Lung Disease Clinic, Mayo Clinic, Rochester, Minnesota

Publisher

American Medical Association (AMA)

Link

https://jamanetwork.com/journals/jama/articlepdf/2819085/jama_zamora_2024_ed_240041_1721921488.54197.pdf

Reference21 articles.

1. Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry.;Behr;Eur Respir J,2020

2. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.;King;N Engl J Med,2014

3. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.;Richeldi;N Engl J Med,2014

4. Meaningful endpoints for idiopathic pulmonary fibrosis (IPF) clinical trials: emphasis on ‘feels, functions, survives’: report of a collaborative discussion in a symposium with direct engagement from representatives of patients, investigators, the National Institutes of Health, a patient advocacy organization, and a regulatory agency.;Raghu;Am J Respir Crit Care Med,2024

5. Zinpentraxin alfa for idiopathic pulmonary fibrosis: the randomized phase III STARSCAPE trial.;Richeldi;Am J Respir Crit Care Med,2024

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3